Why the study?
Does L-arterenol improve outcomes in patients with shock due to acute myocardial infarction?
Does L-arterenol improve outcomes in patients with shock due to acute myocardial infarction?
This text discusses the early rationale for using L-arterenol (norepinephrine) to treat severe cardiogenic shock complicating acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
Supports norepinephrine in post-MI cardiogenic shock; extends early RCT rationale for vasopressor therapy.
THE OCCURRENCE of severe shock following myocardial infarction has generally been considered of such grave prognostic import as almost to negate the possibility of effective therapy. It remains true that shock is a grave prognostic indication, but it is encouraging to find more investigators directing their attention to a reasonable therapeutic approach. Inasmuch as the degree of shock is not necessarily in direct proportion to the size of the infarct, it is not unlikely that the resolution of the shock state could lead to recovery in a proportion of the patients who now succumb. Rosenbaum and Levine¹reported a 51% mortality rate for cases of infarction complicated by moderate shock and a 93% mortality for those with severe shock. They considered the prognosis grave if the blood pressure remained at 80 mm. Hg or less for any length of time. Katz and Mintz²found that a systolic blood
No takes yet. Share an insight, caveat, or question.
Albert J. Miller (1952) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: